Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost

Adv Ther. Nov-Dec 2002;19(6):275-81. doi: 10.1007/BF02853173.

Abstract

This open-label, monocular, two-phase trial was conducted to determine whether bimatoprost is effective in patients with open-angle glaucoma or ocular hypertension not responsive to latanoprost. After a 4-week washout of any ocular hypotensive agents, patients with IOP between 22 and 34 mm Hg (n=51) instilled latanoprost in one eye and were evaluated at weeks 4 and 8 (phase 1). Patients with an IOP reduction no more than 3 mm Hg at both visits were considered nonresponders to latanoprost and were switched to bimatoprost for 8 weeks (n=21) (phase 2). In the treated eyes, the mean reduction in IOP from baseline after 4 weeks of each medication was 2.3 mm Hg with latanoprost (P=.012) and 6.1 mm Hg with bimatoprost (P<.001). After 8 weeks, respective IOP reductions were 1.9 mm Hg (P=.027) and 5.4 mm Hg (P<.001). After the switch from latanoprost, 8 weeks of bimatoprost provided an additional mean IOP reduction of 3.5 mm Hg (P<.001).

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amides
  • Antihypertensive Agents / therapeutic use*
  • Bimatoprost
  • Cloprostenol / analogs & derivatives
  • Female
  • Glaucoma, Open-Angle / drug therapy*
  • Humans
  • Latanoprost
  • Lipids / therapeutic use*
  • Male
  • Middle Aged
  • Ocular Hypertension / drug therapy*
  • Prostaglandins F, Synthetic / therapeutic use
  • Treatment Failure

Substances

  • Amides
  • Antihypertensive Agents
  • Lipids
  • Prostaglandins F, Synthetic
  • Cloprostenol
  • Latanoprost
  • Bimatoprost